Adjusted global antiphospholipid syndrome score (aGAPSS) is useful to predict relapses in patients with retinal vein occlusion

Background A significant proportion of patients with retinal vein occlusion (RVO) are antiphospholipid antibodies (aPL) carriers. Relapsing disease occurs in nearly 10 % of cases and the role of aPL has not been established. The adjusted global antiphospholipid syndrome score (aGAPSS) was developed...

Descripción completa

Detalles Bibliográficos
Autores: Hernández Hernández, José Luis, Napal, José J., Icardo Colvée, Miguel, González Bores, Paula, Pérez-Montes, R., Cerveró Varona, Andrea|||0000-0002-1780-8239, Salmón, Zaida, Olmos Martínez, José Manuel, Martínez Taboada, Víctor Manuel
Tipo de recurso: artículo
Fecha de publicación:2023
País:España
Institución:Universidad de Cantabria (UC)
Repositorio:UCrea Repositorio Abierto de la Universidad de Cantabria
Idioma:inglés
OAI Identifier:oai:repositorio.unican.es:10902/27279
Acceso en línea:https://hdl.handle.net/10902/27279
Access Level:acceso abierto
Palabra clave:Retinal vein occlusion
Antiphospholipid antibodies
Antiphospholipid syndrome
Relapses
Adjusted global antiphospholipid syndrome score
id ES_e8a96cfdf7c164d3059ec271840aae9d
oai_identifier_str oai:repositorio.unican.es:10902/27279
network_acronym_str ES
network_name_str España
repository_id_str
spelling Adjusted global antiphospholipid syndrome score (aGAPSS) is useful to predict relapses in patients with retinal vein occlusionHernández Hernández, José LuisNapal, José J.Icardo Colvée, MiguelGonzález Bores, PaulaPérez-Montes, R.Cerveró Varona, Andrea|||0000-0002-1780-8239Salmón, ZaidaOlmos Martínez, José ManuelMartínez Taboada, Víctor ManuelRetinal vein occlusionAntiphospholipid antibodiesAntiphospholipid syndromeRelapsesAdjusted global antiphospholipid syndrome scoreBackground A significant proportion of patients with retinal vein occlusion (RVO) are antiphospholipid antibodies (aPL) carriers. Relapsing disease occurs in nearly 10 % of cases and the role of aPL has not been established. The adjusted global antiphospholipid syndrome score (aGAPSS) was developed to assess the risk of clinical events in aPL carriers and its role in the management of RVO patients is unknown. Objective To analyze the values of aGAPSS in a large cohort of patients with RVO and population-based controls, and to assess its usefulness to predict RVO relapses. Methods Case-control study of RVO patients and population-based controls of similar age and sex. We have assessed and compared the aPL profile and the aGAPSS score in patients with and without relapsing disease and controls. Results Four-hundred and seventy-two RVO patients and 346 controls were included. Fifty-seven RVO patients had antiphospholipid syndrome (RVO-APS). Of them, 75.4 % had a high-risk profile compared to 3 % in controls (p = 0.0001). The median aGAPSS values were 8 [7?13], 3 [1?4], and 3 [0?4], in RVO-APS, RVO no-APS, and controls. Nineteen patients had had a recurrence of RVO before inclusion and 8 during the follow-up. APS was more prevalent in relapsing patients. In the adjusted multivariable regression model, the best predictor for RVO recurrence during the follow-up was an aGAPSS score ?6 (OR 5.5, CI95% 1.3?23.7; p = 0.023). Conclusions In patients with RVO, once the control of vascular risk factors has been optimized, the aGAPSS might help to identify those at risk of relapsing disease.Sources of funding: The Camargo Cohort Study was supported by a grant from Instituto de Salud Carlos III (PI21/00532) that could be co-funded by European Union FEDER funds.ElsevierUniversidad de Cantabria20232023-01-01journal articlehttp://purl.org/coar/resource_type/c_6501NAhttp://purl.org/coar/version/c_be7fb7dd8ff6fe43info:eu-repo/semantics/articlehttps://hdl.handle.net/10902/27279Thrombosis Research, 2023, 221, 113-119reponame:UCrea Repositorio Abierto de la Universidad de Cantabriainstname:Universidad de Cantabria (UC)Inglésengopen accesshttp://purl.org/coar/access_right/c_abf2Attribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccessoai:repositorio.unican.es:10902/272792026-06-02T12:39:31Z
dc.title.none.fl_str_mv Adjusted global antiphospholipid syndrome score (aGAPSS) is useful to predict relapses in patients with retinal vein occlusion
title Adjusted global antiphospholipid syndrome score (aGAPSS) is useful to predict relapses in patients with retinal vein occlusion
spellingShingle Adjusted global antiphospholipid syndrome score (aGAPSS) is useful to predict relapses in patients with retinal vein occlusion
Hernández Hernández, José Luis
Retinal vein occlusion
Antiphospholipid antibodies
Antiphospholipid syndrome
Relapses
Adjusted global antiphospholipid syndrome score
title_short Adjusted global antiphospholipid syndrome score (aGAPSS) is useful to predict relapses in patients with retinal vein occlusion
title_full Adjusted global antiphospholipid syndrome score (aGAPSS) is useful to predict relapses in patients with retinal vein occlusion
title_fullStr Adjusted global antiphospholipid syndrome score (aGAPSS) is useful to predict relapses in patients with retinal vein occlusion
title_full_unstemmed Adjusted global antiphospholipid syndrome score (aGAPSS) is useful to predict relapses in patients with retinal vein occlusion
title_sort Adjusted global antiphospholipid syndrome score (aGAPSS) is useful to predict relapses in patients with retinal vein occlusion
dc.creator.none.fl_str_mv Hernández Hernández, José Luis
Napal, José J.
Icardo Colvée, Miguel
González Bores, Paula
Pérez-Montes, R.
Cerveró Varona, Andrea|||0000-0002-1780-8239
Salmón, Zaida
Olmos Martínez, José Manuel
Martínez Taboada, Víctor Manuel
author Hernández Hernández, José Luis
author_facet Hernández Hernández, José Luis
Napal, José J.
Icardo Colvée, Miguel
González Bores, Paula
Pérez-Montes, R.
Cerveró Varona, Andrea|||0000-0002-1780-8239
Salmón, Zaida
Olmos Martínez, José Manuel
Martínez Taboada, Víctor Manuel
author_role author
author2 Napal, José J.
Icardo Colvée, Miguel
González Bores, Paula
Pérez-Montes, R.
Cerveró Varona, Andrea|||0000-0002-1780-8239
Salmón, Zaida
Olmos Martínez, José Manuel
Martínez Taboada, Víctor Manuel
author2_role author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Universidad de Cantabria
dc.subject.none.fl_str_mv Retinal vein occlusion
Antiphospholipid antibodies
Antiphospholipid syndrome
Relapses
Adjusted global antiphospholipid syndrome score
topic Retinal vein occlusion
Antiphospholipid antibodies
Antiphospholipid syndrome
Relapses
Adjusted global antiphospholipid syndrome score
description Background A significant proportion of patients with retinal vein occlusion (RVO) are antiphospholipid antibodies (aPL) carriers. Relapsing disease occurs in nearly 10 % of cases and the role of aPL has not been established. The adjusted global antiphospholipid syndrome score (aGAPSS) was developed to assess the risk of clinical events in aPL carriers and its role in the management of RVO patients is unknown. Objective To analyze the values of aGAPSS in a large cohort of patients with RVO and population-based controls, and to assess its usefulness to predict RVO relapses. Methods Case-control study of RVO patients and population-based controls of similar age and sex. We have assessed and compared the aPL profile and the aGAPSS score in patients with and without relapsing disease and controls. Results Four-hundred and seventy-two RVO patients and 346 controls were included. Fifty-seven RVO patients had antiphospholipid syndrome (RVO-APS). Of them, 75.4 % had a high-risk profile compared to 3 % in controls (p = 0.0001). The median aGAPSS values were 8 [7?13], 3 [1?4], and 3 [0?4], in RVO-APS, RVO no-APS, and controls. Nineteen patients had had a recurrence of RVO before inclusion and 8 during the follow-up. APS was more prevalent in relapsing patients. In the adjusted multivariable regression model, the best predictor for RVO recurrence during the follow-up was an aGAPSS score ?6 (OR 5.5, CI95% 1.3?23.7; p = 0.023). Conclusions In patients with RVO, once the control of vascular risk factors has been optimized, the aGAPSS might help to identify those at risk of relapsing disease.
publishDate 2023
dc.date.none.fl_str_mv 2023
2023-01-01
dc.type.none.fl_str_mv journal article
http://purl.org/coar/resource_type/c_6501
NA
http://purl.org/coar/version/c_be7fb7dd8ff6fe43
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://hdl.handle.net/10902/27279
url https://hdl.handle.net/10902/27279
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
Attribution-NonCommercial-NoDerivatives 4.0 International
http://creativecommons.org/licenses/by-nc-nd/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
Attribution-NonCommercial-NoDerivatives 4.0 International
http://creativecommons.org/licenses/by-nc-nd/4.0/
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv Elsevier
publisher.none.fl_str_mv Elsevier
dc.source.none.fl_str_mv Thrombosis Research, 2023, 221, 113-119
reponame:UCrea Repositorio Abierto de la Universidad de Cantabria
instname:Universidad de Cantabria (UC)
instname_str Universidad de Cantabria (UC)
reponame_str UCrea Repositorio Abierto de la Universidad de Cantabria
collection UCrea Repositorio Abierto de la Universidad de Cantabria
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869422960956145664
score 15,300719

Similares en LA Referencia